Role of Peritoneal Ultrafiltration in Heart Failure Treatment


Creative Commons License

Senel T. E. , Cebeci E., Ozturk S.

HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, vol.55, no.3, pp.165-174, 2017 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Review
  • Volume: 55 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.4274/haseki.81894
  • Title of Journal : HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI
  • Page Numbers: pp.165-174

Abstract

Cardiorenal syndrome (CRS) is a general term that can reflect different clinical conditions in which cardiac and renal dysfunctions coexist. The main pathogenetic mechanisms playing a role in heart failure (HF) and CRS are neurohumoral adaptation, right ventricular dilatation and dysfunction and systemic inflammation. Persistence of these factors cause focal and segmental glomerulosclerosis, and tubulointerstitial fibrosis in the renal parenchyma. Diuretics, beta blockers, reninangiotensin-aldosterone system inhibitors, and vasodilators are the main medical treatments besides conventional approach, such as salt and water restriction and quitting smoking, in HF treatment. Diuretic resistance is the main problem emerging during diuretic treatments. Two renal replacement treatments have become prominent for removal of excess fluids via ultrafiltration in HF patients with diuretic resistance extracorporeal ultrafiltration with hemodialysis and peritoneal dialysis (PD). Herein, the role of these two ultrafiltration modalities, especially peritoneal ultrafiltration (PUF) in the treatment of HF is discussed. The main studies and advantages of PUF in HF treatment were discussed. Moreover, effects of PD on glomerular filtration rate, hospitalization and mortality were investigated. In conclusion, PD is an alternative cheap, practical and convenient therapy in reducing cardiac volume burden in HF patients who do not respond well to standard treatments and/or require frequent hospitalization.